149 related articles for article (PubMed ID: 7862445)
1. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.
Hartmann A; Blaszyk H; McGovern RM; Schroeder JJ; Cunningham J; De Vries EM; Kovach JS; Sommer SS
Oncogene; 1995 Feb; 10(4):681-8. PubMed ID: 7862445
[TBL] [Abstract][Full Text] [Related]
2. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis.
Saitoh S; Cunningham J; De Vries EM; McGovern RM; Schroeder JJ; Hartmann A; Blaszyk H; Wold LE; Schaid D; Sommer SS
Oncogene; 1994 Oct; 9(10):2869-75. PubMed ID: 8084591
[TBL] [Abstract][Full Text] [Related]
3. Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer.
Jolly KW; Malkin D; Douglass EC; Brown TF; Sinclair AE; Look AT
Oncogene; 1994 Jan; 9(1):97-102. PubMed ID: 8302608
[TBL] [Abstract][Full Text] [Related]
4. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
5. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
Casey G; Lopez ME; Ramos JC; Plummer SJ; Arboleda MJ; Shaughnessy M; Karlan B; Slamon DJ
Oncogene; 1996 Nov; 13(9):1971-81. PubMed ID: 8934544
[TBL] [Abstract][Full Text] [Related]
6. Molecular epidemiology of breast cancers in northern and southern Japan: the frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations.
Blaszyk H; Hartmann A; Tamura Y; Saitoh S; Cunningham JM; McGovern RM; Schroeder JJ; Schaid DJ; Ii K; Monden Y; Morimoto T; Komaki K; Sasa M; Hirata K; Okazaki M; Kovach JS; Sommer SS
Oncogene; 1996 Nov; 13(10):2159-66. PubMed ID: 8950983
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
8. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
10. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.
Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA
Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641
[TBL] [Abstract][Full Text] [Related]
11. p53 mutations in human lung tumors.
Miller CW; Simon K; Aslo A; Kok K; Yokota J; Buys CH; Terada M; Koeffler HP
Cancer Res; 1992 Apr; 52(7):1695-8. PubMed ID: 1312896
[TBL] [Abstract][Full Text] [Related]
12. An abundance of p53 null mutations in ovarian carcinoma.
Skilling JS; Sood A; Niemann T; Lager DJ; Buller RE
Oncogene; 1996 Jul; 13(1):117-23. PubMed ID: 8700537
[TBL] [Abstract][Full Text] [Related]
13. Splicing mutations of the p53 gene in human hepatocellular carcinoma.
Lai MY; Chang HC; Li HP; Ku CK; Chen PJ; Sheu JC; Huang GT; Lee PH; Chen DS
Cancer Res; 1993 Apr; 53(7):1653-6. PubMed ID: 8384081
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the conserved regions of p53 are infrequent in betel-associated oral cancers from Papua New Guinea.
Thomas S; Brennan J; Martel G; Frazer I; Montesano R; Sidransky D; Hollstein M
Cancer Res; 1994 Jul; 54(13):3588-93. PubMed ID: 8012986
[TBL] [Abstract][Full Text] [Related]
16. P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.
Forslund A; Kressner U; Lönnroth C; Andersson M; Lindmark G; Lundholm K
Int J Oncol; 2002 Aug; 21(2):409-15. PubMed ID: 12118339
[TBL] [Abstract][Full Text] [Related]
17. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
18. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
[TBL] [Abstract][Full Text] [Related]
19. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.
Komuro H; Hayashi Y; Kawamura M; Hayashi K; Kaneko Y; Kamoshita S; Hanada R; Yamamoto K; Hongo T; Yamada M
Cancer Res; 1993 Nov; 53(21):5284-8. PubMed ID: 8221663
[TBL] [Abstract][Full Text] [Related]
20. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
Gao H; Wang LD; Zhou Q; Hong JY; Huang TY; Yang CS
Cancer Res; 1994 Aug; 54(16):4342-6. PubMed ID: 8044781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
